Recombinant PreS‐fusion protein vaccine for birch pollen and apple allergy

• DOI: 10.1111/all.15919
• Publication Date: 2023-10-19T07:50:05Z
• Authors: Musa Khaitov; Igor Shilovskiy; Rudolf Valenta; Milena Weber; Artem Korneev; Inna Tulaeva; Pia Gattinger; Marianne van Hage; Gerhard Hofer; Jon R. Konradsen; Walter Keller; Oluwatoyin Akinfenwa; Alina Poroshina; Nataliya Ilina; Elena Fedenko; Olga Elisyutina; Alla Litovkina; Evgenii Smolnikov; Aleksandra Nikonova; Sergei Rybalkin; Vladimir Aldobaev; Valeriy Smirnov; Nadezhda Shershakova; Olga Petukhova; Dmitriy Kudlay; Artem Shatilov; Anastasiya Timofeeva; Raffaela Campana; Sergei Udin; Veronica Skvortsova
• Keywords: Hypoallergenic; Basophil activation; Blocking antibody

Abstract Background IgE cross‐sensitization to major birch pollen allergen Bet v 1 and pathogenesis‐related (PR10) plant food allergens is responsible for the pollen‐food allergy syndrome. Methods We designed a recombinant protein, AB‐PreS, consisting of non‐allergenic peptides derived from IgE‐binding sites cross‐reactive apple allergen, Mal d 1, fused PreS domain HBV surface protein as immunological carrier. AB‐PreS was expressed in E. coli purified by chromatography. The allergenic inflammatory activity tested using basophils PBMCs allergic patients. ability antibodies induced immunization rabbits with extract‐based vaccines inhibit patients binding assessed ELISA. Results experiments basophil activation test revealed hypoallergenic nature AB‐PreS. lower T‐cell cytokine production cultured IgG five injections inhibited patients' better than did up 30 six licensed vaccines. Additionally, HBV‐specific potentially protecting infection HBV. Conclusion AB‐PreS‐based vaccine superior over currently registered regarding induction blocking animals.